More recently, omega-3 fatty acids, which are known agonists of FFAR1 and FFAR4, have shown efficacy in treating NAFLD, NASH, alcoholic hepatitis, and IFALD. This evidence concerns the gene FFAR4 and metabolic dysfunction-associated steatotic liver disease.